Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Maveropepimut-S |
Synonyms | |
Therapy Description |
DPX-Survivac (maveropepimut-S) is a liposome-encapsulated cancer vaccine that contains Survivin epitopes, which may induce an immune response against Survivin-expressing tumor cells (PMID: 26405584). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Maveropepimut-S | DPX-Survivac|MVP-S | DPX-Survivac (maveropepimut-S) is a liposome-encapsulated cancer vaccine that contains Survivin epitopes, which may induce an immune response against Survivin-expressing tumor cells (PMID: 26405584). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04920617 | Phase II | Maveropepimut-S Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab | DPX-Survivac, Alone or in Combination With Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | ROU | POL | NZL | HUN | FRA | ESP | CAN | AUS | 1 |
NCT03349450 | Phase II | Cyclophosphamide + Maveropepimut-S + Pembrolizumab Maveropepimut-S | DPX-Survivac and Checkpoint Inhibitor in DLBCL (SPiReL) | Completed | CAN | 0 |